Equity Analysis /
United States of America

US : Flexion Therapeutics, Inc. - FLXN | 2Q21 Preview - Zilretta Set For Sequential Gain As Metrics Support Our Long-Term Projections

    Michael Parolari
    Michael Parolari

    Research Associate

    CGS-CIMB
    1 August 2021
    Published by